title: Quantified short-term outcome of uterine artery embolization with gelatin sponge particles and lipiodol for symptomatic myoma.
abstract: OBJECTIVE
  To investigate and quantify clinical outcomes and spectral Doppler analyses of uterine arteries in patients with myoma undergoing uterine artery embolization (UAE) with gelatin sponge particles and lipiodol.
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  Tertiary medical center.
  
  
  METHODS
  Forty premenopausal women with symptomatic myoma.
  
  
  METHODS
  Uterine artery embolization with gelatin sponge particles and lipiodol.
  
  
  METHODS
  Hemoglobin, hematocrit, CA-125, pictorial blood loss assessment, visual analogue pain scale, questionnaire for symptoms, tumor volume, and spectral Doppler analyses of uterine arteries.
  
  
  RESULTS
  The mean follow-up period was 8.1 months (range, 6-12). Menstrual flow improved in 29 of 35 patients (83%) and decreased significantly by 78.4%. Menstrual pain improved in 27 of 35 patients (77%) and decreased significantly by 70%. Hematocrit and CA-125 improved significantly. The mean percentage reductions of uterine and myomal volumes were 40.2% and 54.9%, respectively. The mean peak systolic velocity of the uterine arteries decreased by 52%. The major complication rate was 2.56%. There was no correlation between tumor volume reduction and clinical outcome.
  
  
  CONCLUSIONS
  Uterine artery embolization with gelatin sponge particles and lipiodol had satisfactory short-term outcomes, comparable to those associated with polyvinyl alcohol particles. Quantified and semiquantified measurements provided objective assessment of clinical outcomes. Serum CA-125 might play a role in clinical follow-up. Reduction of tumor volume is not predictive of UAE efficacy.
authors.affiliation: Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Huang
authors.forename: Yu-Fan
authors.initials: YF
authors.lastname: Cheng
authors.forename: Hsueh-Wen
authors.initials: HW
authors.lastname: Chang
authors.forename: Shiuh-Young
authors.initials: SY
authors.lastname: Chang
authors.forename: Fu-Tsai
authors.initials: FT
authors.lastname: Kung
authors.forename: Hsi-Mi
authors.initials: HM
authors.lastname: Liang
authors.forename: Kuan-Hui
authors.initials: KH
authors.lastname: Huang
mesh_terms: D000328:Adult; D018394:CA-125 Antigen / Q000097:blood; D004621:Embolization, Therapeutic; D005260:Female; D005780:Gelatin; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D007889:Leiomyoma / Q000628:therapy*; D008875:Middle Aged; D011142:Polyvinyl Alcohol / Q000008:administration & dosage; D011446:Prospective Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000628:therapy*
chemical_list: D018394:CA-125 Antigen; D006454:Hemoglobins; D007459:Iodized Oil; D005780:Gelatin; D011142:Polyvinyl Alcohol